Sex-Specific Presentation and Response to Long-Term Rituximab in Phospholipase A2 Receptor (PLA2R)-Positive Membranous Nephropathy (KIDNEY WEEK 2026) - Oct 2, 2026 - Abstract #FR-PO0818; Pres time: Oct 23, 2026; 10:00 AM - 12:00 PM; Location: Exhibit Hall A, Convention Center; "Higher rituximab doses are associated with greater antibody reduction but did not accelerates response. Changes in eGFR were greater in females, reaching statistical significance at 48 months, with a consistent trend toward higher eGFR over time despite comparable baseline values between sexes.Overall, females demonstrated more favorable clinical outcomes, although immunologic response to rituximab was similar across sexes"
Glomerulonephritis • Immunology • Renal Disease
|
|
Maria J. Vargas-Brochero; Matheus Vieira Falcao; Anila Cara; Cristián Juanet; Ilario Russo; Fernando C. Fervenza; Maria Jose Soler Romeo
|